Changing the History of Prostate Cancer with New Targeted Therapies
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted therapies for the treatment of different molecular subtypes. Some biomarkers are described as potential molecular targets different from classic androgen receptors (A...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2021-04-01
|
| Collection: | Biomedicines |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2227-9059/9/4/392 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|